Data & Policies

SASB

Biotechnology Pharmaceuticals

Accounting Metric

HC-BP-210a.1
Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials. We operate a system to protect the safety and rights of clinical test participants
We operate a system to protect the safety and rights of clinical test participants
Product/Service Responsibilities/.../Product Safety Management
HC-BP-210a.3
Total amount of monetary losses as a result of legal proceedings
Violations of regulations related to clinical trials in developing countries: 0, monetary losses(fines): 0

HC-BP-240a.2
List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP).
We obtained WHO PQ Certification for SKY Cellflu Trivalent and Quadrivalent Prefilled
Syringe and Sky Varicella in 2019 Drug safety
Business Introduction/.../<Developed Vaccines>

HC-BP-250a.3
Number of recalls issued, total units recalled.
The number of recalls: 0,
Total number of units recalled: 0
HC-BP-250a.4
Total amount of product accepted for take-back, reuse, or disposal.
The total number of products accepted for take-back, reuse, or disposal: 0

HC-BP-270a.1
Total amount of monetary losses as a result of legal proceedings associated with false marketing claims.
The number of violations related to domestic marketing activities: 0, total amount of monetary losses(fines): 0.
HC-BP-270a.2
Description of code of ethics governing promotion of off-label use of products.
We do not conduct any kind of marketing or promotion that may induce off-label prescriptions.

HC-BP-330a.1
Discussion of talent recruitment and retention efforts for scientists and research and development personnel.
By defining core competencies for our future business, we expanded target recruitment to attract qualified candidates, and operate HR system for employee growth.
The number of our researchers continues to grow from 121 in 2019, to 146 in 2020, and 208 in 2021.

HC-BP-510a.1
Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery
Fines related to unfair business practices as a result of violation of competition and antitrust laws (including corruption and bribery): 0
HC-BP-510a.2
Description of code of ethics governing interactions with health care professionals
We apply compliance regulations for responsible marketing activities.
We have separate procedures for pre-inspection and post-evaluation of compliance regulations during marketing activities.